Back
Schall, Brown & Schwartz investigates Alnylam after 2026 TTR sales guidance cut sparks 28.4% stock drop

Schall, Brown & Schwartz investigates Alnylam after 2026 TTR sales guidance cut sparks 28.4% stock drop

The firm said it is examining whether Alnylam misled investors after the company trimmed full-year 2026 TTR product sales guidance following its latest earnings update.

Fact Check
The caller-supplied PRNewswire release explicitly confirms Schall, Brown & Schwartz LLP (SBS Law) is investigating Albertsons for potential securities violations following the July 23, 2026 Q1 miss and lowered full-year EPS outlook. Independent sources (Morningstar/Levi & Korsinsky notice, stockanalysis.com) corroborate that Albertsons missed Q1 2026 expectations and cut its full-year earnings guidance, causing a sharp share-price decline. Every element of the claim is supported by consistent, mutually reinforcing sources.
    Reference: 123
Summary

Schall, Brown & Schwartz LLP said it is investigating potential securities-law violations by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors. The firm said the probe centers on whether Alnylam made false or misleading statements or failed to disclose information material to shareholders. The inquiry follows Alnylam's July 30, 2026 second-quarter results, when the company said it had lowered full-year 2026 TTR product sales guidance to reflect what it learned from the initial phase of its launch in the evolving ATTR-CM market, including the normalization of growth in second-line volume after pent-up demand from patients waiting for a new therapy was satisfied. The release said shares fell almost 28.4% that day. Schall, Brown & Schwartz said investors who suffered losses can contact Brian Schall or David Schwartz for more information.

Terms & Concepts
  • sales guidance: A company's forecast for future revenue or product sales.
  • ATTR-CM: Transthyretin amyloid cardiomyopathy, a heart disease market tied here to demand for Alnylam's TTR products.
  • TTR product sales: Revenue from products related to transthyretin, the protein targeted by Alnylam's therapy franchise.